获取途径

作者

Huansheng Wang Hao Li Yinping Yuan Ting Hao Benkui Zou Bing Yu Sheng Li Jianbo Zhang

作者单位

Cheeloo College of Medicine，Shandong University，Jinan，China；Shandong Cancer Hospital and Institute，Shandong First Medical University and Shandong Academy of Medical Sciences，Jinan，China；Clinical Laboratory，Shandong Pharmaceutical Research Institute，Jinan，China；Shandong Cancer Hospital and Institute，Shandong First Medical University and Shandong Academy of Medical Sciences，Jinan，China；Shandong Cancer Hospital and Institute，Shandong First Medical University and Shandong Academy of Medical Sciences，Jinan，China；Shandong Cancer Hospital and Institute，Shandong First Medical University and Shandong Academy of Medical Sciences，Jinan，China；Clinical Laboratory，Shandong Pharmaceutical Research Institute，Jinan，China；Cheeloo College of Medicine，Shandong University，Jinan，China；Clinical Laboratory，Shandong Pharmaceutical Research Institute，Jinan，China；Shandong Cancer Hospital and Institute，Shandong First Medical University and Shandong Academy of Medical Sciences，Jinan，China

刊名

泌尿男科转化医学杂志

年份

2022

卷号

第11卷

期号

第4期

页码

460-471

关键词

Renal cell cancer (RCC) circulating tumor cells (CTCs) epithelial-mesenchymal transition

摘要

Background Circulating tumor cells are considered useful prognostic factors for various cancers, and in 2014, our research group conducted a comparative experiment of CTC detection in patients with renal cell cancer . However, the reason for the low detection rate of CTCs in cancer patients using the CellSearch® system is still unknown, although it has been hypothesized to be attributed to the likelihood that CTCs undergoing epithelial-mesenchymal transition do not express the CTC biomarkers c...更多

Background Circulating tumor cells are considered useful prognostic factors for various cancers, and in 2014, our research group conducted a comparative experiment of CTC detection in patients with renal cell cancer . However, the reason for the low detection rate of CTCs in cancer patients using the CellSearch® system is still unknown, although it has been hypothesized to be attributed to the likelihood that CTCs undergoing epithelial-mesenchymal transition do not express the CTC biomarkers cytokeratin 8/18/19 or epithelial cell adhesion molecule . The overall aim of the current study was to investigate the expression levels of CK8/18/19 and EpCAM in relation to the EMT biomarkers vimentin and E-cadherin in patients with RCC. Methods Patients with RCC who had undergone radical nephrectomy or partial resection between May 2014 and December 2014 were initially recruited. Results Among 34 RCC patients, nine co-expressed EpCAM and CK8/18/19 in primary tumor tissues. The CellSearch® results showed that CK8/18/19 was expressed in 5 of 6 patients and EpCAM was expressed in 6 patients . However, the isolation by size of tumor cells technique showed these were co-expressed in only four of the 10. The expression of CK8/18/19, EpCAM, vimentin, and E-cadherin was distributed unequally in different enumeration groups of CTCs , and the positive expression of CK8/18/19 was correlated with neutrophil number and tumor size . The positive expression of vimentin was correlated with the Karnofsky Performance Status score and clinical stage of renal cancer patients . Conclusions Our results indirectly proved the occurrence of EMT in the formation of CTCs by comparing and analyzing the expression of CK8/18/19 and EpCAM in renal cancer tissues and the detection results of CTCs.收起

文献类型

期刊